Latest Postherpetic neuralgia Stories
MENLO PARK, Calif., Sept. 14, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the UBS Global Life Sciences Conference in New York City. The presentation at the UBS conference is scheduled for 10:30 a.m. EDT (7:30 a.m. PDT) on Wednesday, September 19, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...
MENLO PARK, Calif., Sept. 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Morgan Stanley Healthcare Conference in New York. The 'unplugged' format at the Morgan Stanley conference is scheduled for 1:00 pm EDT (10:00 am PDT) on Wednesday, September 12. The session will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived...
AACHEN, Germany, September 5, 2012 /PRNewswire/ -- Targeted Treatment for Patients Suffering from Postherpetic Neuralgia: It's a Control Thing - This press Information is meant exclusively for trade press. - We do not approve publication in lay press. Ask pain patients what they expect from their treatment and the answer is simple: "I want to sleep through the whole night," or, "I want to be able to walk with my wife." They want relief with minimal side...
MELBOURNE, Australia, August 28, 2012 /PRNewswire/ -- Trial Meets Primary Endpoint: Reduction in Pain Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals. The...
MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology. Under the terms of the agreement Janssen received a non-exclusive license and other rights to certain Acuform patents. In exchange, Depomed will receive an upfront payment of $10 million and will receive a low single digit royalty on net sales of NUCYNTA® ER (tapentadol...
MENLO PARK, Calif., Aug. 24, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Stifel Nicolaus Healthcare Conference in Boston. The presentation at the Stifel Nicolaus conference is scheduled for 10:55 a.m. EDT (7:55 a.m. PDT) on Wednesday, September 5, 2012. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be...
MENLO PARK, Calif., July 31, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes. "We are pleased to achieve this milestone in our Serada program. We believe that if approved Serada will offer women a non-hormonal option for...
MENLO PARK, Calif., July 30, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second quarter fiscal year 2012 financial results after the market closes on Thursday, August 2, 2012. The company will host a conference call beginning at 5:00 pm Eastern time, 2:00 pm California time to discuss its results. Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international). The conference call will also be...
MENLO PARK, Calif, July 23, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that a report of Phase 3 data published online this month, ahead of the print edition, in the Clinical Journal of Pain showed that once-daily Gralise(®) (gabapentin) tablets (1,800 mg) formulation significantly reduces intensity of pain in patients with postherpetic neuralgia (PHN). The results showed that patients treated with Gralise experienced a significant reduction (- 2.12) in...
MENLO PARK, Calif., July 6, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the JMP Securities 7th Annual Healthcare Conference in New York City. The presentation at the JMP conference is scheduled for 10:00 am EDT (7:00 am PDT) on Friday, July 13. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for...
Latest Postherpetic neuralgia Reference Libraries
Herpes zoster (or zoster), is known as shingles or zona and is a viral disease characterized by painful skin rash with blisters in a limited area on one side of the body. Initial infection causes chickenpox. Once chickenpox is over the virus remains in the body and can cause shingles. It can become latent in the nerve cell bodies and sometimes in the dorsal root, cranial nerve, or autonomic ganglion. Years after initial infection, another breakout can cause a painful rash. The rash usually...
